Dallah Healthcare
4004 · TASI — Main Market · 2026-07-29
Download report (PDF)
Snapshot Price 105.40 SAR
Market cap 10.67B SAR
P/E 19.82×
P/B 2.61×
ROE 13.19%
Dividend yield 1.96%
Revenue CAGR 17.89%
Valuation (Hajras) Fair value 46.47 SAR
Rating overvalued
Upside/(downside) -55.92%
DCF 7.71
DDM 35.12
Graham 66.55
Discount rate 9.05%
DCF growth 8.00%
Financials SAR FY21 FY22 FY23 FY24 FY25 Revenue 2.11B 2.49B 2.94B 3.21B 4.07B Net income 258.60M 274.46M 360.12M 471.20M 538.27M EPS 2.56 2.71 3.56 4.66 5.32 DPS 1.61 1.78 1.52 1.99 2.06 Equity 1.87B 1.99B 3.20B 3.47B 4.08B
Analyst Price Targets Consensus (median) — SAR
Range — – — SAR
Aljazira Capital (hold) 117.00 SAR
This report is for informational purposes only and is not investment advice. Sources: Hajras valuation & financials, Yahoo/SEC EDGAR, and investment-house targets.